Spotlight on Life Sciences

November, 2017:  Innovation and the Financial Impact Along the Drug Development Path

Presented by  Sponsored by  Innovation often starts the drug discovery process, but innovation also inspires change in development, manufacturing, supply chain, and drug delivery in nearly every step of the drug development continuum. The financial impact can also be seen at all levels of development. The debate over rising drug prices has become a full-blown blaming game with drug companies pointing the finger at middlemen in the health-care system, saying they not only benefit from rising drug prices but contribute to their increases…Who is responsible for high drug pricing? The Irish Chamber’s third annual Life Sciences Forum brings a unique and deep perspective to this debate. Click to view interviews with each panel members:

Dr Garrett FitzGerald: https://live.securebroadcast.com/file/PE0V4J883AGI4S9/

 

Dr Andrea Perrone: https://live.securebroadcast.com/file/EHOWK1K8KRAE87T/

 

Paul McCracken: https://live.securebroadcast.com/file/I90GAYKP8CMBE4J/

 

Jo Sirianni: https://live.securebroadcast.com/file/K87BF3KHEFFNSYA/

 

~~

Panel Members Key Note Speaker: Dr. Garret FitzGerald, MD, FRS
Director, Institute for Translational Medicine & Therapeutics, University of Pennsylvania

Dr. FitzGerald is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he chairs the Department of Systems Pharmacology and Translational Therapeutics and directs the Institute for Translational Medicine and Therapeutics. Dr. FitzGerald’s research has been characterized by an integrative approach to elucidating the mechanisms of drug action, drawing on work in cells, model organisms and humans. His work contributed fundamentally to the development of low-dose aspirin for cardioprotection. FitzGerald’s group was the first to predict and then mechanistically explain the cardiovascular hazard from NSAIDs. He has also discovered many products of lipid peroxidation and established their utility as indices of oxidant stress in vivo. His laboratory was the first to discover a molecular clock in the cardiovascular system and has studied the importance of peripheral clocks in the regulation of cardiovascular and metabolic function. Dr. FitzGerald has received the Boyle, Coakley, Harvey and St. Patrick’s Day medals, the Lucian, Scheele and Hunter Awards, the Presidential Award for the Irish Abroad and the Cameron, Taylor, Herz, Lefoulon-Delalande, and Schottenstein Prizes. He is a member of the National Academy of Medicine, an honorary member of the Royal Irish Academy and a Fellow of the American Academy of the Arts and Sciences and of the Royal Society.

~~

Dr. Andrea Perrone, MD
Associate Vice President, Clinical Imaging Translational Medicine, Merck & Co

Dr. Perrone joined Merck 5 years ago and is currently the Associate Vice President of Clinical Imaging in Translational Medicine. She and her team provide imaging expertise in protocol development, execution and regulatory support for clinical trials of therapeutic agents across all disease indications. Prior to joining Merck, Dr Perrone was the Head of Late Clinical Development at GE Healthcare contributing to new ultrasound, CT and PET imaging agents. Other roles include VP, Clinical Operations and Medical Director at BioClinica as well as Director, Clinical Development at a biomarker discovery start-up, SurroMed that was subsequently acquired by PPD. She obtained a BS in Finance from the University of Maryland and then transitioned into the sciences. Dr Perrone completed medical school and an internship at Georgetown University Medical School as well as a radiology residency at the University of Pittsburgh.

~~

Mr. Joseph Sirianni
Senior Director Global Engineering Services,
Zoetis

Mr. Sirianni is currently the Senior Director Global Engineering  at Zoetis.  He was responsible for the design of the global function and instrumental in the evaluation of the Pfizer Animal Health Engineering Organization, development of the Engineering support model for Zoetis including the  separation of manufacturing operations from Pfizer. At Zoetis he leads a group of technical experts that guide the execution of capital investments, bring technologies to manufacturing for new products and enabling efficient manufacturing processes. Prior to the stand-up of Zoetis Joe was a technical leader in the Pfizer global engineering group responsible for supporting a number of manufacturing sites in technical areas including, capital execution, maintenance reliability and process/ packaging technologies for pharm and biologics operations.  Prior to Pfizer he lead the design and Pharmaceutical engineering functions for several Architectural and Engineering Firms including AMEC and bioKinetics.   Joe has a BSME from Boston University.

~~

Moderator: Paul McCracken Ph.D.
Vice President, Head of Medical Imaging,
ICON plc.

Dr. McCracken has over 20 years’ experience in imaging and pharmaceuticals, with a strong track record of applying imaging and biomarkers to drug discovery and development across a range of therapeutic areas. Dr. McCracken joined ICON from Eisai, where he led the Imaging Centre of Excellence, which drives novel approaches for discovery targets and translational biomarkers, primarily through the introduction of imaging genetics and the acceleration of novel PET approaches. Prior to Eisai, Paul worked at Merck Research Laboratories, where he developed preclinical and translational imaging biomarkers and strategies to assess new molecular and biologic entities. Dr. McCracken holds a Bachelor of Science in Physics from The College of New Jersey, a Master of Science in Physics/Medical Physics from Wright State University and received his Ph.D. in Biomedical Engineering – Imaging from the Mayo Clinic College of Medicine

~~

Companies Represented at this event:

Thank you to our 2017 Ambassador Club Sponsors:

November, 2016: Exploring Big Pharma’s Role in Shaping Patient Wellness and Our Economy Hosted by the Irish American Business Chamber & Network and Almac Group, in conjunction with the British American Business Council of Greater Philadelphia, this interactive symposium features pharmaceutical/life sciences and commercial industry experts that will discuss major trends in drug development, the cost of healthcare and impact on patients and our economy. Learning Objectives • The industry’s greatest challenges and the next generation of future collaborations that will be needed • The impact of the pharmaceutical industry on the broader economy • The pharmaceutical business model and risk profile • Understand patient advocacy and engagement: – The voice of patients: what do they want and need? – What is personalized medicine and how can it change healthcare? – The role of clinical trials and the value to patients and industry. – Patient advocacy groups and how they improve communication and engagement. Meet Our Panelists Key Note Speaker: Brendan Fenton is Regional Finance Director, Australia, Canada and Western Europe, Bristol-Myers Squibb. Brendan has been in the Pharmaceutical Industry for 30 years, 10 years with Johnson and Johnson in South Africa and Switzerland; 20 with BMS in Japan China and Asian Pack, South America, Middle East and Russia; andCFO of  the Virology and Immunology Business in the USA. Brendan was born in County Cork, Ireland and educated at University College Cork where he majored in Finance and Law. Brendan earned his MBA from the Haub School of Business at Saint Joseph’s University in Philadelphia. ~~ John Barry is Head of Portfolio Sourcing and Relationship Management (PSRM), Merck Research Laboratories at Merck & Co and currently looks over an external spend in excess of $1B (USD) across a variety of sourcing models. His team is responsible for supplier oversight and governance, demand management and earned value management across Merck’s late stage development portfolio. External relationships under Barry’s leadership include organizations that provide CRO, ARO, Laboratory, IVRS, ePro, Imaging and other functional and category based services. The portfolio of resources required to prosecute Merck’s clinical trial programs exceeds 5500 people with a majority of these staff provided via external partners. John brings an alliance management orientation to Merck’s supplier partnerships to ensure consistent and reliable delivery within and across the supplier portfolio. He comes to Merck with over twenty years of supplier side experience working for two of the top 5 global CROs. Throughout his career at these CROs he was responsible for or was an executive leader in a variety of functions including Alliance Management, Business Development, Clinical Operations, Contracts, Proposals and Legal. Notably, he was responsible for creating and leading a new profit center focused on functional service model provision for Quintiles and grew that division to over 1100 professionals in under 14 months. His is well versed in a variety of contract structures including value based contracting and has significant experience negotiating innovative commercial and capital models. Barry has a B.S. from Cornell University and an MBA from the University of North Carolina at Chapel Hill. ~~ Michael Sapienza , Chief Executive Officer of The Colon Cancer Alliance, lost his mother to the disease in May 0f 2009 and served as President and Founder of The Chris4Life Colon Cancer Foundation from 2010 – 2015. He has turned his profound grief into action, inspiring and challenging the colorectal cancer community, family, friends and professional associates to follow his lead and dedicate themselves to this cause and the Colon Cancer Alliance mission. Michael was an integral member of the team that led the effort to merge the Colon Cancer Alliance, and the Chris4Life Colon Cancer Foundation creating the nation’s largest colon cancer specific nonprofit. Michael is a member of The Ruesch Center for the Cure of GI Cancer’s Advisory board at Georgetown University. In 2014, Michael received three prestigious industry awards; the David Jagelman, MD Award for advocacy in Colorectal Cancer Awareness by the American Society of Colon and Rectal Surgeons, the Public Service Award from the Society of Surgery of the Alimentary Tract, and the Champion Award from Preventing Colorectal Cancer. He regularly appears on TV, and radio programs throughout the United States to promote the importance of increased funding for colorectal cancer research, and early detection. Michael holds degrees from both Northwestern University and Rice University and currently resides in the District of Columbia. ~~ Moderator: George Tiger Vice President, Global Business Development, Clinical Technologies, Almac Group George Tiger joined Almac Group in June 2015 as Vice President, Global Business Development – Clinical Technologies and is responsible for global sales, marketing, and commercial operations. In addition to directing sales strategy and execution, George is actively involved in helping to drive growth for Almac across business units in key strategic areas and expanding Almac business worldwide. George comes to Almac with over 25 years of success in sales, marketing, and general management, most recently as Sr. Vice President, Life Sciences Sales for Health Market Science and Sr. Vice President, Global Sales for ERT, a leading supplier of cardiac safety, respiratory, and eCOA solutions, where he served in a series of management positions of increasing responsibility the US, Europe and Globally. Prior to ERT, George served as Vice President Sales and Marketing with Celsis International plc and Celsis Laboratory Group.   George began his business career with Abbott Laboratories, Diagnostics Division in field sales and product management. He is a graduate of Lafayette College, with a BA in Economics and Business, where he played 4 years of Division I soccer prior to playing professional soccer for five years after graduation. About Our Venue Almac Group’s North American Headquarters, Souderton, PA    Companies represented

Thank You to Our Event Partner Thank You to Our 2016 Ambassador Club Sponsors